发布2020年第五期国家药品标准物质供应新情况,包括18个即将上市的新品种,49个即将换批品种的预计上市时间, 46个即将失效品种的有效使用期限和3个停用品种名单,详见表1、表2,表3和表4。 表1:即将上市的新品种 序号 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 新型冠状病毒IgM抗体检测试剂(酶免法)国家参考品 | | | | | 新型冠状病毒IgG抗体检测试剂(酶免法)国家参考品 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
表2:即将换批的品种
序号 | | | | | | | 磷酸奥司他韦杂质Ⅲ ((3R,4R,5S)-4-乙酰胺基-5-氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
表3:即将失效的品种 序号 | | | | | | | 磷酸奥司他韦杂质Ⅲ ((3R,4R,5S)-4-乙酰胺基-5-氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
表4近期停用的品种 对于有效使用期限外的标准物质以及未规定有效使用期限的非最新批次标准物质(一般指在国家药品标准物质供应目录中不收载的老旧批次),我院将不再对其进行质量监测,用户如若继续使用,其特性量值及适用性请自行验证。若出现同批品种在不同期发布信息不同的情况,以最新一期的公告内容为准;若在使用期限时间范围内发布了品种停用信息,以停用信息为准。 中国食品药品检定研究院 标准物质和标准化管理中心 2020年5月6日
|